Browsing by Author "S. Nidhinandana"

Filter results by typing the first few letters
Now showing 1 - 3 of 3
  • No Thumbnail Available
    PublicationMetadata only
    Efficacy study of galantamine in possible Alzheimer's disease with or without cerebrovascular disease and vascular dementia in Thai patients: A slow-titration regimen
    (2006-05-01) Nantika Thavichachart; K. Phanthumchinda; S. Chankrachang; R. Praditsuwan; S. Nidhinandana; V. Senanarong; N. Poungvarin; Chulalongkorn University; Chiang Mai University; Mahidol University; Phramongkutklao College of Medicine
    The objective is to evaluate the efficacy of galantamine when a slow titration regimen is employed in Thai Alzheimer's disease (AD) patients with or without cerebrovascular disease and vascular dementia (VaD). A 6-month, multicentre, open-label, uncontrolled trial was undertaken in 75 AD patients. Eligible patients received an initial galantamine dose of 8 mg/day and escalated over 5-8 weeks to maintenance doses of 16 or 4mg/day. Primary efficacy measures were AD Assessment Scale-cognitive subscale (ADAS-cog) and the Clinician's Interview-Based Impression of Change-Plus version (CIBIC-plus). The Behavioural Pathology in AD Rating Scale (BEHAVE AD), the AD Cooperative Study Activities of Daily Living Inventory and Pittsburgh Sleep Quality Index were the secondary efficacy variables. Analyses were based on the intent-to-treat population. Treatment with galantamine showed significant improvement in cognition on the ADAS-cog and CIBIC-plus at month 6. Galantamine showed favourable effects on activities of daily living. Behavioural symptoms and sleep quality were also significantly improved (p < 0.05). Galantamine was well tolerated. The adverse events were mild-to-moderate intensity. The most frequent adverse events commonly reported were nausea (16.4%), dizziness (9.6%) and vomiting (6.8%). The results of this study may be consistent with galantamine being an effective and safe treatment for mild-to-moderate AD patients with or without cerebrovascular disease and VaD. Flexible dose escalation of galantamine was well tolerated. The daily maintenance dose of galantamine was 16 mg/day, followed by a back up dose of 24 mg/day. © Blackwell Publishing Ltd, 2006.
  • No Thumbnail Available
    PublicationMetadata only
    Galantamine for the treatment of BPSD in Thai patients with possible Alzheimer's disease with or without cerebrovascular disease
    (2009-01-01) S. Tangwongchai; N. Thavichachart; V. Senanarong; N. Poungvarin; K. Phanthumchinda; R. Praditsuwan; S. Nidhinandana; S. Chankrachang; Chulalongkorn University; Faculty of Medicine, Chiang Mai University; Mahidol University; Pramongkutklao Hospital
    Objectives. This study was to investigate an efficacy of galantamine in treatment of behavioral and psychological symptoms of dementia in Thai elderly who suffered from possible Alzheimer's disease (AD) with or without cerebrovascular disease and vascular dementia. Methods. A 6-month, multicenter, open-label, uncontrolled trial was undertaken in 75 patients. Eligible patients received an initial galantamine dose of 8 mg/dayand escalated over 5 to 8 weeks to maintenance doses of 16 or 24 mg/day. The behavioral response was assessed as an intention-to-treat analysis using the Behavioral Pathology in Alzheimer's Disease Rating Scale (BEHAVE-AD). Results. Galantamine improved behavioral and psychological symptoms of dementia (P <.05 vs baseline) over the 24 weeks of treatment. BEHAVE-AD score was significantly improved from baseline in paranoid and delusion ideation, diurnal rhythm disturbances, anxieties, and phobias. Conclusions. Galantamine may be a well-tolerated and effective treatment option for improving psychotic, behavioral, and psychological symptoms in Thai elderly with possible AD with or without cerebrovascular disease and vascular dementia. © 2009 Sage Publications.
  • No Thumbnail Available
    PublicationMetadata only
    Neuropsychological abnormalities in patients with dementia in CRF 01_AE HIV-1 infection
    (2007-02-01) V. G. Valcour; P. Sithinamsuwan; S. Nidhinandana; S. Thitivichianlert; S. Ratto-Kim; W. Apateerapong; B. T. Shiramizu; M. S. DeSouza; S. T. Chitpatima; G. Watt; T. Chuenchitra; K. R. Robertson; R. H. Paul; J. C. McArthur; J. H. Kim; C. M. Shikuma; University of Hawaii at Manoa John A. Burns School of Medicine; The University of North Carolina at Chapel Hill; University of Missouri-St. Louis; Johns Hopkins University; Phramongkutklao Hospital; Phramongkutklao Hospital; Armed Forces Research Institute of the Medical Sciences; Mahidol University; Armed Forces Research Institute of Medical Sciences, Thailand; Leahi Hospital
    HIV-associated dementia (HAD) is not firmly established in patients with circulating recombinant form (CRF) 01_AE HIV-1. In this study, we compared neuropsychological performance among 15 Thai individuals with HAD, 15 Thai individuals without HAD, and 30 HIV-negative control subjects. HIV-1 participants were highly active anti-retroviral therapy naive and matched by age, education, and CD4 count. Neuropsychological testing abnormalities were identified in most cognitive domains among HAD vs HIV-negative participants, confirming the presence of HAD in CRF01_AE. ©2007AAN Enterprises, Inc.